TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy
Liqin Zhao, Xiaofei Qu, Zhenhua Wu, Yuehua Li, Xiaowei Zhang, Weijian Guo
Abstract
mutation status also improves the prognostic prediction in NSCLC patients that underwent immunotherapy.
Topics & Concepts
Somatic cellImmunotherapyLung cancerMedicineCancerOncologyCancer researchBiologyImmunologyInternal medicineGeneticsGeneLung Cancer Treatments and MutationsCancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers